Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results-Reference-Cited by-同舟云学术

Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results

Published:2020-09-06 Issue:12 Volume:22 Page:2209-2226
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Pantalone Kevin M.¹^ORCID,Munir Kashif²,Hasenour Clinton M.³,Atisso Charles M.³,Varnado Oralee J.³^ORCID,Maldonado Juan M.³,Konig Manige³

Affiliation:

1. Cleveland Clinic Endocrinology and Metabolism Institute Cleveland Ohio

2. Center for Diabetes and Endocrinology University of Maryland Baltimore Maryland

3. Eli Lilly and Company Indianapolis Indiana

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14165

Reference39 articles.

1. American Heart Association. Cardiovascular Disease and Diabetes.https://www.heart.org/en/health-topics/diabetes/why-diabetes-matters/cardiovascular-disease--diabetes. Accessed August 16 2019.

2. Gender Difference in the Impact of Type 2 Diabetes on Coronary Heart Disease Risk

3. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus

4. Economic Costs of Diabetes in the U.S. in 2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP-1 Receptor Agonists Critical Review: Revisiting Its Positioning for Type 2 Diabetes Mellitus in Routine Clinical Practice in India;Clinical Diabetology;2022-08-31

2. Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials;Journal of the American Heart Association;2022-06-07

3. Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A meta‐analysis and meta‐regression analysis;Diabetes, Obesity and Metabolism;2022-02-21

4. Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth;Diabetology International;2021-11-25

5. Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND , LEADER and SUSTAIN ‐6 to the real‐world type 2 diabetes population in the United Kingdom;Diabetes, Obesity and Metabolism;2021-11-24